HB26-1056 creates the "Prescription Drug Optimized Sourcing Transparency and Integrity Act" and is aimed at prescription drug purchasing arrangements used by self-insured employers. The bill defines and recognizes "pharmacy stewardship programs" and "prescription drug optimized sourcing programs" as lawful cost-containment tools when they comply with federal law, including programs that may use personal-use importation or other authorized sourcing channels. It also states that these programs are not insurance, a health plan, a PBM, or a third-party administrator, and that prescriptions not filled through the program continue to be processed through the plan’s existing pharmacy benefit manager, carrier, and network.
The bill would prohibit pharmacy benefit managers and health-care consultants from knowingly making false or misleading statements to employers, self-insured employers, or policyholders about the legality or safety of a lawful optimized sourcing program. It would also require PBMs and consultants, upon written request from a self-insured employer, to provide detailed prescription-level cost information, including total drug cost, member-paid amount, plan/employer-paid amount, and drug-identifying information such as NDC, quantity, strength, and days’ supply. The bill further bars withholding, editing, or redacting that requested information.
In addition, the bill expressly preserves a self-insured employer’s right to contract for lawful prescription drug optimized sourcing programs and says the measure does not create a new insurance product, mandatory coverage, or a state fiscal mandate. Enforcement would be handled by the insurance commissioner, and violations would be treated as unfair methods of competition and unfair or deceptive acts or practices under Colorado insurance law, with each day of violation counted separately. The act would take effect after the referendum period, with applicability only to conduct occurring on or after the effective date.
The overall sentiment reflected in the bill text is strongly supportive of transparency, employer autonomy, and cost reduction in prescription drug benefits. The legislative declaration frames the measure as protecting employers and plan sponsors, supporting patient safety, and reducing unnecessary costs while preserving clinical decision-making. However, the bill’s posture in committee suggests it did not advance, as the House Health & Human Services Committee postponed it indefinitely.
The main point of contention appears to be the role of PBMs and health-care consultants in relation to optimized sourcing and importation programs. The bill is designed to prevent those entities from discouraging such programs through allegedly misleading claims and to force disclosure of detailed cost data, which may be viewed as burdensome or as exposing proprietary plan information. The inclusion of personal-use importation and the bill’s explicit endorsement of pharmacy stewardship programs likely also raise policy concerns for opponents worried about safety, regulatory complexity, or disruption to existing pharmacy benefit arrangements.
The bill would add a new section to Colorado insurance law governing PBMs and health-care consultants that serve self-insured health plans, and it would also add a corresponding unfair-practices provision to the state’s insurance code. It would require disclosure of detailed prescription cost data on request, prohibit misleading statements about lawful optimized sourcing programs, and authorize enforcement by the insurance commissioner as an insurance violation. The measure would not mandate participation by employers, create a new insurance product, or require new state spending, but it would expand state oversight of PBM and consultant conduct in the self-insured employer market.
The bill’s stated purpose and structure indicate a pro-transparency, pro-employer, and pro-cost-containment sentiment. It presents prescription drug optimized sourcing and pharmacy stewardship programs as legitimate tools to lower plan costs while maintaining safety and continuity of care. At the same time, the fact that the House Health & Human Services Committee postponed the bill indefinitely suggests there was not enough support to move it forward, likely reflecting skepticism about the policy approach or its effects on existing pharmacy benefit arrangements.
The central controversy is whether PBMs and health-care consultants should be compelled to facilitate and disclose information about prescription drug optimized sourcing programs, including importation-based arrangements, rather than steering employers toward traditional networks. Supporters would likely argue that employers need accurate information and full cost transparency to manage self-insured plans effectively, while opponents may argue that the bill intrudes on PBM operations, could expose sensitive pricing data, and may encourage sourcing models that raise safety or regulatory concerns. The bill’s explicit protection of lawful importation and its characterization of these programs as not being insurance may also be contentious for stakeholders concerned about federal preemption, regulatory boundaries, or patient safety oversight.